Table 7.

Targeted agents used as radiosensitisers in preclinical studies using BCa xenografts.

Class	Name	Target	Cell Line Subtype (According to [46])	Year	Ref.
TKI	Gefitinib (ZD1839)	EGFR	J82, non-luminal, non-basal	2007	[70]
	Afatinib, Erlotinib	EGFR/HER2, EGFR	NTUB1, class n/a	2015	[98]
PI3K	LY294002	PI3 kinase	T24, non-luminal, non-basal	2003	[66]
Epigenetic modifiers	Panobinostat	HDAC (histone deacetylase)	RT112, luminal	2018	[55]
	Romidepsin	HDAC (histone deacetylase)	RT112, luminal	2020	[57]
Heat shock protein inhibitors	17-AAG or 17-DMAG	Hsp90	UMUC3 non-luminal, non-basal	2011	[69]
Farnesyltransferase inhibitors	FTI-276 and L744832	Farnesyltransferase	T24, non-luminal, non-basal	2000	[67]
Hypoxia	AQ4N	Hypoxia	RT112, luminal	2009	[56]
Angiogenesis	SQAP	Angiogenesis	5637, basal	2016	[62]
Other	Chloroquine	Autophagy	T24, non-luminal, non-basal	2018	[64]
	HSA-MnO2-CQ nanoparticles	Autophagy	T24, non-luminal, non-basal	2020	[65]
	Ad-RSV-CD+5-FC	-	KK47, non-luminal, non-basal	2003	[71]
	shRNF8	DNA Damage Response	T24, non-luminal, non-basal	2016	[63]
	Caffeine	DNA Damage Response	RT4, luminal	2015	[60]
	siTUG1	HMGB1	SW780, luminal	2017	[61]
	shHMGB1	HMGB1	UMUC3 non-luminal, non-basal	2016	[68]
	Flutamide/shAR	AR	UMUC3 non-luminal, non-basal	2018	[53]
	Photofrin II	Angiogenesis	RT4, luminal	2001	[59]
	Low-fibre, soluble high-fibre, insoluble high-fibre, and mixed soluble/insoluble high-fibre diets	Metabolism	RT112, luminal	2020	[58]

Abbreviations: 17-AAG: 7-N-allylamino-17-demethoxygeldanamycin; 17-DMAG: 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; AQ4N: banoxantrone dihydrochloride, topoisomerase II inhibitor; AR: androgen receptor; HER2: human erbB-2 receptor; HMGB1: high mobility group box 1; HSA-MnO2-CQ: MnO2 and chloroquine in human serum albumin (HSA)-based nanoplatform; RNF8: ring finger protein 8; SQAP: sulfoquinovosylacylpropanediol; TKI: tyrosine kinase inhibitor; TUG1: taurine-upregulated gene 1.